Focuses on developing gene therapies for monogenic diseases of the central nervous system and other severe genetic disorders.
Taysha Gene Therapies, Inc. is a pioneering gene therapy company dedicated to advancing adeno-associated virus-based treatments for monogenic diseases of the central nervous system. At the forefront of its development efforts are multiple promising therapies, including TSHA-120 for giant axonal neuropathy, TSHA-102 for Rett syndrome, TSHA-121 and TSHA-118 for CLN1 disease, TSHA-105 for SLC13A5 Deficiency, and TSHA-101 for GM2 gangliosidosis. These therapies aim to address critical unmet medical needs by targeting the underlying genetic causes of these debilitating conditions.
Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies has established a strategic partnership with The University of Texas Southwestern Medical Center. This collaboration focuses on harnessing transformative gene therapy innovations to develop and commercialize groundbreaking treatments. Through cutting-edge research and development, Taysha Gene Therapies is committed to bringing hope to patients and families affected by rare genetic disorders, striving to deliver therapies that can potentially alter the course of these devastating diseases.
With a visionary approach and a robust pipeline of therapies in various stages of development, Taysha Gene Therapies is poised to make significant advancements in the field of gene therapy. By leveraging scientific expertise and strategic collaborations, the company aims to accelerate the availability of life-changing treatments and improve outcomes for patients worldwide.